Phase II Study of HER2 Imaging as Biomarker for T-DM1 in Advanced Breast Cancer

The ZEPHIR-02 trial's focus on HER2 imaging as a predictive biomarker could significantly influence treatment sequencing in HER2-positive breast cancer. If successful, it may establish HER2-PET/CT as a standard biomarker, impacting future treatment guidelines and competitive dynamics for Roche's T-DM1.

The ZEPHIR-02 trial's focus on HER2 imaging as a predictive biomarker could significantly influence treatment sequencing in HER2-positive breast cancer. If successful, it may establish HER2-PET/CT as a standard biomarker, impacting future treatment guidelines and competitive dynamics for Roche's T-DM1.

Trial Update

The ZEPHIR-02 trial will evaluate 89Zr-trastuzumab PET/CT as a predictive biomarker for T-DM1 treatment in HER2-positive mBC patients post T-DXd progression.

The ZEPHIR-02 trial's focus on HER2 imaging as a predictive biomarker could significantly influence treatment sequencing in HER2-positive breast cancer. If successful, it may establish HER2-PET/CT as a standard biomarker, impacting future treatment guidelines and competitive dynamics for Roche's T-DM1.

Monitor enrollment progress, interim results on treatment responses, and any updates on metabolic evaluations from the trial.